Pharmion drug gets fast-track status

MichelleDonley

NEW YORK (MarketWatch) -- Pharmion Corp.
PHRM
said Wednesday that the Food and Drug Administration has granted fast-track status for oral azacitidine in the treatment of myelodysplastic syndromes, or MDS. The Boulder-Colo.-based drugmaker now markets azacitidine for injection, branded as Vidaza, to treat MDS, in which bone marrow fails to produce enough blood cells. The FDA's fast-track designation is designed to expedite the application and review process for products that have the potential to address a serious or life-threatening condition.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.